ClinicalTrials.gg
CompletedNCT03250793NAVA-DIAPHUpdated Sep 4, 2025

Work of Breathing Description in Neonates With Congenital Diaphragmatic Hernia in NAVA and in Conventional Ventilation.

An interventional study of Physiologic study measuring work of breathing which can be estimated by the esophageal and trans-diaphragmatic pressure-time product obtained by an esophageal transducer in Hernia, DIaphragmatic, Congenital, sponsored by Hospices Civils de Lyon. Completed at 1 site in France. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
1 Year and older
Sex
All
01

Study summary

Congenital diaphragmatic hernia (CDH) is a congenital malformation associated with significant mortality and respiratory morbidity, particularly related to prolonged mechanical ventilation. NAVA (Neurally Adjusted Ventilatory Assist) is a recent technique that uses the recognition of the electrical activity of the patient's diaphragm (Edi) and delivers a synchronized proportional assisted ventilation. This technique has already been used in the newborn, especially premature and has shown many benefits. Only one study in the literature shows its feasibility in newborns with CDH. This technique seems interesting in the context of CDH because it would limit baro-trauma and improve synchronization. Before demonstrating the clinical benefits, it seems important to describe the effects on the respiratory physiology, in particular on work of breathing which can be estimated by the esophageal and trans-diaphragmatic pressure-time product obtained by an esophageal transducer. Our study is an innovative physiologic pilot study with the objective to describe work of breathing in neonates with CDH in post-surgical period in NAVA ventilation and in conventional ventilation using an esophageal transducer. It will provide the clinician with a physiological justification for the use of NAVA to rapidly improve the respiratory muscular dynamics of these patients. This study is a prerequisite for the realization of studies demonstrating the clinical benefit of NAVA ventilation on reduction of duration of ventilation and more generally on morbidity and mortality in the population of neonate with CDH.

02

Conditions studied

  • Hernia, DIaphragmatic, Congenital

Browse trials for

Keywords

  • Hernia, DIaphragmatic, Congenital
  • Respiration, Artificial
  • physiologic pilot study
  • NAVA
  • Neurally Adjusted Ventilatory Assist
  • esophageal transducer
  • Work of Breathing
03

In context

Hernia, Diaphragmatic

23 studies on the registry are indexed under Hernia, Diaphragmatic; 4 are open to participants now.

This study's enrollment of 8 is below the median of 33 across 17 interventional studies indexed under Hernia, Diaphragmatic.

Browse Hernia, Diaphragmatic studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,866 studies on the registry; 448 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Neonate admitted to neonatal intensive care beyond 34 weeks of amenorrhea
  • With a diagnosis of congenital diaphragmatic hernia having undergone a repair surgery.
  • Necessary invasive ventilatory support by conventional ventilation
  • Informed and signed consent of parents (and / or holders of parental authority)

Exclusion criteria

Exclusion Criteria:

  • Refusal of parents (and / or holders of parental authority) to participate in the study
  • to the use of an oro or naso-gastric tube (oesophageal surgery)
  • Child at risk of poor tolerance to the placement of the oesophageal pressure transducer (history of discomfort when placing a tube, weight \<1500g)
  • Central or neuromuscular neurological pathology which may affect respiratory control
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Neonate with congenital diaphragmatic hernia

    Neonates with congenital diaphragmatic hernia in post-surgical period under mechanical ventilation during weaning of mechanical ventilation

    Device: Physiologic study measuring work of breathing which can be estimated by the esophageal and trans-diaphragmatic pressure-time product obtained by an esophageal transducer

Interventions

  • DevicePhysiologic study measuring work of breathing which can be estimated by the esophageal and trans-diaphragmatic pressure-time product obtained by an esophageal transducer

    While the patient is under respiratory assistance on the SERVO-I respirator, he will be included in the study and one esophageal transducer of 2,3 mm of diameter will be inserted through the mouth / nose in addition to NAVA's naso / Oro-Gastric tube( Edi Catheter, 6Fr, 49 cm, PHT free 5 pcs / pkg or Catheter Edi, 6Fr, 50 cm, PHT free 5 pcs / pkg). Measurements will be performed using the esophageal transducer under two conditions: 2 hours in conventional ventilation (pressure controlled), 2 hours in NAVA ventilation and then again 2 hours in conventional ventilation (PC) for a total duration of 6 hours.The parameters of conventional ventilation will be left free at the choice of the neonatologist and will be identical between the two periods of conventional ventilation. The initial NAVA level will be defined by the neonatologist using pre-visualization curves. All signals will be recorded via an amplification and acquisition system. Values will be averaged over 100 cycles.

06

What researchers measure

Primary outcomes

  1. Work of breathing averaged over 100 consecutive cycles in NAVA ventilation and conventional ventilation

    Work of breathing is estimated by the esophageal and trans-diaphragmatic pressure-time product obtained by an esophageal transducer

    Time frame: in post-surgical period during 6 hours

Secondary outcomes

  1. Patient-ventilator synchronization in NAVA

    Comparison of the asynchrony indexes between the 2 modes (Number of asynchronies / Number of respiratory cycles)

    Time frame: through study completion, an average of 1 year

  2. Patient-ventilator synchronization in conventional ventilation

    Comparison of the asynchrony indexes between the 2 modes (Number of asynchronies / Number of respiratory cycles)

    Time frame: through study completion, an average of 1 year

  3. Dynamic hyperinflation (intrinsic PEEP) in NAVA

    Intrinsic PEEP average over 100 cycles

    Time frame: through study completion, an average of 1 year

  4. Dynamic hyperinflation (intrinsic PEEP) in conventional ventilation.

    Intrinsic PEEP average over 100 cycles

    Time frame: through study completion, an average of 1 year

  5. Ventilation parameters: peak inspiratory pressure in NAVA

    Evolution of the following parameters: peak inspiratory pressure, mean pressure, tidal volume, Ti / Ttot ration, FiO2

    Time frame: through study completion, an average of 1 year

  6. Ventilation parameters: mean pressure in NAVA

    Evolution of the following parameters: peak inspiratory pressure, mean pressure, tidal volume, Ti / Ttot ration, FiO2

    Time frame: through study completion, an average of 1 year

  7. Ventilation parameters: tidal volume in NAVA

    Evolution of the following parameters: peak inspiratory pressure, mean pressure, tidal volume, Ti / Ttot ration, FiO2

    Time frame: through study completion, an average of 1 year

  8. Ventilation parameters: Ti / Ttot ratio in NAVA

    Evolution of the following parameters: peak inspiratory pressure, mean pressure, tidal volume, Ti / Ttot ration, FiO2

    Time frame: through study completion, an average of 1 year

  9. Ventilation parameters: FiO2 in NAVA

    Evolution of the following parameters: peak inspiratory pressure, mean pressure, tidal volume, Ti / Ttot ration, FiO2

    Time frame: through study completion, an average of 1 year

  10. Ventilation parameters: peak inspiratory pressure in conventional ventilation

    Evolution of the following parameters: peak inspiratory pressure, mean pressure, tidal volume, Ti / Ttot ration, FiO2

    Time frame: through study completion, an average of 1 year

  11. Ventilation parameters: mean pressure in conventional ventilation

    Evolution of the following parameters: peak inspiratory pressure, mean pressure, tidal volume, Ti / Ttot ration, FiO2

    Time frame: through study completion, an average of 1 year

  12. Ventilation parameters: tidal volume in conventional ventilation

    Evolution of the following parameters: peak inspiratory pressure, mean pressure, tidal volume, Ti / Ttot ration, FiO2

    Time frame: through study completion, an average of 1 year

  13. Ventilation parameters: Ti / Ttot ratio in conventional ventilation

    Evolution of the following parameters: peak inspiratory pressure, mean pressure, tidal volume, Ti / Ttot ration, FiO2

    Time frame: through study completion, an average of 1 year

  14. Ventilation parameters: FiO2 in conventional ventilation

    Evolution of the following parameters: peak inspiratory pressure, mean pressure, tidal volume, Ti / Ttot ration, FiO2

    Time frame: through study completion, an average of 1 year

  15. Physiological parameters indirectly evaluating work of breathing: esophageal swing in NAVA

    Averages of the esophageal and diaphragmatic swings over 100 cycles in each period. Esophageal and diaphragmatic swings are physiological parameters obtained by the esophageal transducer which expressed muscle strength.

    Time frame: through study completion, an average of 1 year

  16. Physiological parameters indirectly evaluating work of breathing: diaphragmatic swing in NAVA

    Averages of the esophageal and diaphragmatic swings over 100 cycles in each period. Esophageal and diaphragmatic swings are physiological parameters obtained by the esophageal transducer which expressed muscle strength.

    Time frame: through study completion, an average of 1 year

  17. Physiological parameters indirectly evaluating work of breathing: esophageal swing in conventional ventilation

    Averages of the esophageal and diaphragmatic swings over 100 cycles in each period. Esophageal and diaphragmatic swings are physiological parameters obtained by the esophageal transducer which expressed muscle strength.

    Time frame: through study completion, an average of 1 year

  18. Physiological parameters indirectly evaluating work of breathing: diaphragmatic swing in conventional ventilation

    Averages of the esophageal and diaphragmatic swings over 100 cycles in each period. Esophageal and diaphragmatic swings are physiological parameters obtained by the esophageal transducer which expressed muscle strength.

    Time frame: through study completion, an average of 1 year

  19. Clinical parameters of neonates: respiratory rate in NAVA

    Evolution of clinical parameters (respiratory rate, heart rate, blood pressure) at the beginning and end of each period

    Time frame: through study completion, an average of 1 year

  20. Clinical parameters of neonates: heart rate in NAVA

    Evolution of clinical parameters (respiratory rate, heart rate, blood pressure) at the beginning and end of each period

    Time frame: through study completion, an average of 1 year

  21. Clinical parameters of neonates: blood pressure in NAVA

    Evolution of clinical parameters (respiratory rate, heart rate, blood pressure) at the beginning and end of each period

    Time frame: through study completion, an average of 1 year

  22. Clinical parameters of neonates: respiratory rate in conventional ventilation

    Evolution of clinical parameters (respiratory rate, heart rate, blood pressure) at the beginning and end of each period

    Time frame: through study completion, an average of 1 year

  23. Clinical parameters of neonates: heart rate in conventional ventilation

    Evolution of clinical parameters (respiratory rate, heart rate, blood pressure) at the beginning and end of each period

    Time frame: through study completion, an average of 1 year

  24. Clinical parameters of neonates: blood pressure in conventional ventilation

    Evolution of clinical parameters (respiratory rate, heart rate, blood pressure) at the beginning and end of each period

    Time frame: through study completion, an average of 1 year

  25. Gas exchange: measurement of transcutaneous SaO2 in NAVA

    Evolution of oxygenation parameters (SpO2) and transcutaneous CO2 (pCO2) during each period. SpO2 and pCO2 are measured continuously; average and median will be valued in each period of the study. No blood test will be required.

    Time frame: through study completion, an average of 1 year

  26. Gas exchange: measurement of transcutaneous pCO2 in NAVA

    Evolution of oxygenation parameters (SpO2) and transcutaneous CO2 (pCO2) during each period. SpO2 and pCO2 are measured continuously; average and median will be valued in each period of the study. No blood test will be required.

    Time frame: through study completion, an average of 1 year

  27. Gas exchange: measurement of transcutaneous pCO2 in conventional ventilation

    Evolution of oxygenation parameters (SpO2) and transcutaneous CO2 (pCO2) during each period. SpO2 and pCO2 are measured continuously; average and median will be valued in each period of the study. No blood test will be required.

    Time frame: through study completion, an average of 1 year

  28. Gas exchange: measurement of transcutaneous SaO2 in conventional ventilation

    Evolution of oxygenation parameters (SpO2) and transcutaneous CO2 (pCO2) during each period. SpO2 and pCO2 are measured continuously; average and median will be valued in each period of the study. No blood test will be required.

    Time frame: through study completion, an average of 1 year

  29. Neonate comfort scores: COMFORT-BEHAVIOR score in NAVA

    Evaluation of comfort (COMFORT-BEHAVIOR scale) at the beginning and at the end of each period.

    Time frame: through study completion, an average of 1 year

  30. Neonate comfort scores: COMFORT-BEHAVIOR score in conventional ventilation

    Evaluation of comfort (COMFORT-BEHAVIOR scale) at the beginning and at the end of each period.

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
  • Service de Réanimation Néonatale- Hôpital Femme Mère Enfant- Hospices Civils de Lyon
    Bron, 69500, France
08

References and documents

Publications

  • Dreyfus L, Butin M, Plaisant F, Claris O, Baudin F. Respiratory physiology during NAVA ventilation in neonates born with a congenital diaphragmatic hernia: The "NAVA-diaph" pilot study. Pediatr Pulmonol. 2023 May;58(5):1542-1550. doi: 10.1002/ppul.26357. Epub 2023 Mar 1. PubMed 36807570 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Jan 2021, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2017
First posted
Aug 16, 2017
StartActual
Aug 20, 2018
Primary completionActual
Jan 20, 2021
CompletionActual
Jan 20, 2021
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03250793
Responsible party
Sponsor
First posted
Aug 16, 2017
Start date
Aug 20, 2018
Primary completion
Jan 20, 2021
Completion
Jan 20, 2021
Last update
Sep 4, 2025

Study contacts

Lélia Dreyfus, MD
principal investigator · Service de Réanimation Néonatale- Hôpital Femme Mère Enfant- Hospices Civils de Lyon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion